Follitropin delta (Rekovelle®)

Assessment Status Assessment process complete
Drug Follitropin delta
Brand Rekovelle®
Indication For controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
Assessment Process
Rapid review commissioned 25/07/2017
Rapid review completed 15/08/2017
Rapid review outcome Full pharmacoeconomic assessment recommended at submitted price.

Reimbursement approved following new price application – February 2019.